Cargando…

Acute pro-B-Cell lymphoblastic leukemia transformed from myelodysplastic syndrome with an ASXL1 missense mutation: A case report with literature review

The development of acute lymphoblastic leukemia (ALL) from myelodysplastic syndrome (MDS) is a very rare event. The current report presents a rare case of a 33-year-old man who was diagnosed with MDS with multiple-lineage dysplasia (MDS-MLD) that transformed into pro-B-ALL. A missense mutation (S123...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Zhi-Ping, Tan, Yan-Hong, Li, Jian-Lan, Xu, Zhi-Fang, Chen, Xiu-Hua, Xu, Lian-Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958712/
https://www.ncbi.nlm.nih.gov/pubmed/29805685
http://dx.doi.org/10.3892/ol.2018.8546
_version_ 1783324282209697792
author Guo, Zhi-Ping
Tan, Yan-Hong
Li, Jian-Lan
Xu, Zhi-Fang
Chen, Xiu-Hua
Xu, Lian-Rong
author_facet Guo, Zhi-Ping
Tan, Yan-Hong
Li, Jian-Lan
Xu, Zhi-Fang
Chen, Xiu-Hua
Xu, Lian-Rong
author_sort Guo, Zhi-Ping
collection PubMed
description The development of acute lymphoblastic leukemia (ALL) from myelodysplastic syndrome (MDS) is a very rare event. The current report presents a rare case of a 33-year-old man who was diagnosed with MDS with multiple-lineage dysplasia (MDS-MLD) that transformed into pro-B-ALL. A missense mutation (S1231F) of the additional sex combs like 1, transcriptional regulator gene was identified, which may have a substantial role in the progression, however does not act as an unfavorable prognostic marker. The patient died during induction chemotherapy. The present study further conducted an analysis on 30 patients to determine progression to ALL. Patients were predominantly male (76.7%, 23/30) with a median age of 56 years (3–90 years). The median time to transformation was 5.5 months (2–50 months). The most common type of MDS with ALL transformation comprised of MDS-excess blasts (MDS-EB; 40%, 12/30), MDS with single-lineage dysplasia (MDS-SLD; 30%, 9/30) and MDS with ring sideroblasts (MDS-RS; 16.7%, 5/30). The majority of the patients transformed to B-cell (66.7%, 16/24) followed by T-cell (33.3%, 8/24) ALL. From the 25 cases where data was available, the complete remission rate was 75% (15/20) with ALL-directed chemotherapy and the median remission duration was 15 months (range 4.5 to 51 months). However, the results indicated that ALL following MDS is characterized by a high rate of early death (20%, 5/25).
format Online
Article
Text
id pubmed-5958712
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-59587122018-05-27 Acute pro-B-Cell lymphoblastic leukemia transformed from myelodysplastic syndrome with an ASXL1 missense mutation: A case report with literature review Guo, Zhi-Ping Tan, Yan-Hong Li, Jian-Lan Xu, Zhi-Fang Chen, Xiu-Hua Xu, Lian-Rong Oncol Lett Articles The development of acute lymphoblastic leukemia (ALL) from myelodysplastic syndrome (MDS) is a very rare event. The current report presents a rare case of a 33-year-old man who was diagnosed with MDS with multiple-lineage dysplasia (MDS-MLD) that transformed into pro-B-ALL. A missense mutation (S1231F) of the additional sex combs like 1, transcriptional regulator gene was identified, which may have a substantial role in the progression, however does not act as an unfavorable prognostic marker. The patient died during induction chemotherapy. The present study further conducted an analysis on 30 patients to determine progression to ALL. Patients were predominantly male (76.7%, 23/30) with a median age of 56 years (3–90 years). The median time to transformation was 5.5 months (2–50 months). The most common type of MDS with ALL transformation comprised of MDS-excess blasts (MDS-EB; 40%, 12/30), MDS with single-lineage dysplasia (MDS-SLD; 30%, 9/30) and MDS with ring sideroblasts (MDS-RS; 16.7%, 5/30). The majority of the patients transformed to B-cell (66.7%, 16/24) followed by T-cell (33.3%, 8/24) ALL. From the 25 cases where data was available, the complete remission rate was 75% (15/20) with ALL-directed chemotherapy and the median remission duration was 15 months (range 4.5 to 51 months). However, the results indicated that ALL following MDS is characterized by a high rate of early death (20%, 5/25). D.A. Spandidos 2018-06 2018-04-20 /pmc/articles/PMC5958712/ /pubmed/29805685 http://dx.doi.org/10.3892/ol.2018.8546 Text en Copyright: © Guo et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Guo, Zhi-Ping
Tan, Yan-Hong
Li, Jian-Lan
Xu, Zhi-Fang
Chen, Xiu-Hua
Xu, Lian-Rong
Acute pro-B-Cell lymphoblastic leukemia transformed from myelodysplastic syndrome with an ASXL1 missense mutation: A case report with literature review
title Acute pro-B-Cell lymphoblastic leukemia transformed from myelodysplastic syndrome with an ASXL1 missense mutation: A case report with literature review
title_full Acute pro-B-Cell lymphoblastic leukemia transformed from myelodysplastic syndrome with an ASXL1 missense mutation: A case report with literature review
title_fullStr Acute pro-B-Cell lymphoblastic leukemia transformed from myelodysplastic syndrome with an ASXL1 missense mutation: A case report with literature review
title_full_unstemmed Acute pro-B-Cell lymphoblastic leukemia transformed from myelodysplastic syndrome with an ASXL1 missense mutation: A case report with literature review
title_short Acute pro-B-Cell lymphoblastic leukemia transformed from myelodysplastic syndrome with an ASXL1 missense mutation: A case report with literature review
title_sort acute pro-b-cell lymphoblastic leukemia transformed from myelodysplastic syndrome with an asxl1 missense mutation: a case report with literature review
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958712/
https://www.ncbi.nlm.nih.gov/pubmed/29805685
http://dx.doi.org/10.3892/ol.2018.8546
work_keys_str_mv AT guozhiping acuteprobcelllymphoblasticleukemiatransformedfrommyelodysplasticsyndromewithanasxl1missensemutationacasereportwithliteraturereview
AT tanyanhong acuteprobcelllymphoblasticleukemiatransformedfrommyelodysplasticsyndromewithanasxl1missensemutationacasereportwithliteraturereview
AT lijianlan acuteprobcelllymphoblasticleukemiatransformedfrommyelodysplasticsyndromewithanasxl1missensemutationacasereportwithliteraturereview
AT xuzhifang acuteprobcelllymphoblasticleukemiatransformedfrommyelodysplasticsyndromewithanasxl1missensemutationacasereportwithliteraturereview
AT chenxiuhua acuteprobcelllymphoblasticleukemiatransformedfrommyelodysplasticsyndromewithanasxl1missensemutationacasereportwithliteraturereview
AT xulianrong acuteprobcelllymphoblasticleukemiatransformedfrommyelodysplasticsyndromewithanasxl1missensemutationacasereportwithliteraturereview